Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.

MLA

Agarwal, Rishu, et al. “Clinicopathological Differences Exist between CALR- and JAK2-Mutated Myeloproliferative Neoplasms despite a Similar Molecular Landscape: Data from Targeted next-Generation Sequencing in the Diagnostic Laboratory.” Annals of Hematology, vol. 96, no. 5, May 2017, pp. 725–32. EBSCOhost, https://doi.org/10.1007/s00277-017-2937-6.

APA

Agarwal, R., Blombery, P., McBean, M., Jones, K., Fellowes, A., Doig, K., Forsyth, C., & Westerman, D. A. (2017). Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. Annals of Hematology, 96(5), 725–732. https://doi.org/10.1007/s00277-017-2937-6

Chicago

Agarwal, Rishu, Piers Blombery, Michelle McBean, Kate Jones, Andrew Fellowes, Ken Doig, Cecily Forsyth, and David A Westerman. 2017. “Clinicopathological Differences Exist between CALR- and JAK2-Mutated Myeloproliferative Neoplasms despite a Similar Molecular Landscape: Data from Targeted next-Generation Sequencing in the Diagnostic Laboratory.” Annals of Hematology 96 (5): 725–32. doi:10.1007/s00277-017-2937-6.